Purpose:To evaluate the efficacy and safety of photoselective laser vaporization of the prostate (PVP) in the treatment of bladder outlet obstruction (BOO) secondary to advanced-stage prostate cancer (PCa).
Background: The study is the first on PVP applied to BOO or urinary retention due to advanced-stage PCa in China.
Patients and Methods: Forty-five patients (mean age 76.13 ± 5.88 years, range 62-89) with BOO or urinary retention secondary to advanced-stage PCa received PVP with a potassium-titanyl-phosphate (KTP) laser. The treatment outcome was evaluated with subjective and objective tests at 1, 3, 6, and 12 months after PVP using the International Prostate Symptom Score (IPSS), quality of life (QoL) score, postvoid residual (PVR) urine volume and maximum urinary flow rate (Qmax). The operative time, indwelling catheterization time, operative complications were also observed.
Results: All 45 patients recovered without incident. The mean operative time was 50 ± 7.6 minutes. The catheterization duration was 3.2 days (range 2-7d). There was significant improvement in Qmax from 7.29 ± 0.93 to 12.16 ± 2.75 mL/sec after treatment at 12 months. Mean PVR volume decreased from 210.94 ± 179.49 to 54.45 ± 33.16 mL. Mean IPSS score decreased from preoperative 28.19 ± 3.64 to postoperative14.61 ± 2.81(P < 0.05), QoL score decreased from 5.03 ± 0.69 to 3.66 ± 0.65(P < 0.05). There were no intraoperative adverse events. Postoperative complications included mild transient hematuria in 12 patients (26.7%) and mild dysuria in 11 patients (24.4%) within 4 weeks.
Conclusions: The clinical results suggest that PVP is a safe, efficient and less-invasive treatment for patients with BOO or urinary retention secondary to advanced-stage prostate cancer.
Written by:
Jin C, Xu YM, Fu Q, Gu B. Are you the author?
Shanghai Sixth People's Hospital, Urology, Shanghai Yishan Road 600, shanghai, China, 200233.
Reference: J Endourol. 2012 May 7. Epub ahead of print.
doi: 10.1089/end.2011.0675
PubMed Abstract
PMID: 22563737
UroToday.com Prostate Cancer Section